Medpace (NASDAQ:MEDP) Price Target Raised to $586.00

Medpace (NASDAQ:MEDP) had its price objective raised by stock analysts at Mizuho from $495.00 to $586.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target would indicate a potential upside of 8.88% from the company’s current price.

Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada dropped their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Robert W. Baird restated a “neutral” rating and set a $547.00 price objective (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Barclays decreased their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Finally, BMO Capital Markets lowered their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a report on Friday, April 24th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $469.50.

Medpace Stock Performance

NASDAQ MEDP opened at $538.23 on Monday. The company’s 50-day moving average price is $467.24 and its 200-day moving average price is $495.50. The stock has a market cap of $15.37 billion, a PE ratio of 33.83, a PEG ratio of 2.73 and a beta of 1.15. Medpace has a 12 month low of $306.70 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm’s revenue for the quarter was up 26.5% on a year-over-year basis. During the same quarter last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, sell-side analysts forecast that Medpace will post 17.04 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Medpace

A number of large investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. boosted its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace during the 4th quarter valued at about $30,000. Elyxium Wealth LLC purchased a new stake in Medpace in the fourth quarter valued at about $30,000. Allied Private Wealth LLC purchased a new stake in Medpace in the second quarter valued at about $31,000. Finally, Basecamp Wealth Advisors LLC boosted its holdings in Medpace by 187.5% in the first quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after acquiring an additional 45 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.